Nuwellis earnings release, August 13, 2026

Nuwellis, Inc. (NUWE) · Form 8-K, Item 2.02 · Filed · SEC filing

August 13, 2026

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded

Gross Margin

Recent capital raise and warrant exercises extend cash runway through second quarter of 2027

Conference call begins at 9:00 a.m. Eastern time today

MINNEAPOLIS – August 13, 2026 – Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and six months ended June 30, 2026.

Second Quarter Results and Recent Highlights:

The second quarter demonstrated continued year-over-year growth, meaningful gross-margin improvement and progress across Nuwellis’ commercial and strategic priorities. The Company enters its next phase focused on increasing the installed based and utilization of Aquadex, building recurring circuit revenue, expanding its position in pediatrics and critical care, and selectively advancing technologies that strengthen its broader cardiorenal platform.

“Nuwellis has an established commercial foundation with differentiated strength in pediatrics and momentum in critical care. Our straightforward objective is to grow recurring revenue, improve operating leverage, and position Nuwellis as the leading precision fluid management company across the cardiorenal continuum,” said Mike McCormick, Nuwellis President and Chief Executive Officer. “The recent infusion of capital strengthens our balance sheet and extends our cash runway, which provides financial flexibility to execute on our strategic priorities. We intend to concentrate our investments where we have clear clinical differentiation, attractive commercial opportunities, and the ability to generate sustainable shareholder value. As part of our strategic plan, we are evaluating opportunities to leverage our commercial infrastructure through complementary products and collaborations that deepen relationships within our existing hospital customers.”

Second Quarter 2026 Financial Results

Revenue for the second quarter of 2026 was $2.0 million, compared with approximately $1.7 million in the prior-year quarter, representing a 14% increase. The increase was driven by higher U.S. circuit and console sales, partially offset by lower technical services, catheter, and international sales.

The Company sold nine consoles during the second quarter, compared with three during the second quarter of 2025. The expanding installed base is expected to bolster growth in recurring circuit revenue, which remains the Company's primary driver of long-term growth.

U.S. circuit and console average selling prices increased approximately 5% and 3%, respectively, compared with the prior-year quarter, reflecting pricing adjustments implemented during the third quarter of 2025.

Gross margin for the second quarter of 2026 was 76%, compared with 56% in the prior-year quarter. The improvement reflected pricing adjustments implemented in 2025, favorable product mix, and our successful transition to contract manufacturing.

Operating expenses were approximately $4.7 million for the second quarter of 2026, compared with $3.9 million in the prior-year period, reflecting planned investments in commercial expansion and product development. Net loss was approximately $4.8 million, including approximately $1.7 million of non-cash warrant valuation expense associated with the June 2026 financing, compared with a net loss of

$12.6 million in the prior-year quarter. Following the effective date of the Company’s most recent reverse stock split on July 2, 2026, the related warrants were reclassified from liability to equity in early July.

As of June 30, 2026, the Company had cash and cash equivalents of approximately $3.9 million. Through second-quarter financing activity and subsequent financing events, Nuwellis raised approximately $12.7 million in gross proceeds, strengthening its cash position and simplifying its capitalization structure. This activity included $6.0 million raised in June and, subsequent to June 30, an additional $3.4 million from a July financing and $3.3 million from warrant exercise proceeds.

Webcast and Conference Call Information

The Company will host a conference call and webcast at 9:00 a.m. Eastern time today to discuss its financial results and provide an update on the Company’s performance.

To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com/.

Alternatively, the live conference call may be accessed by dialing (833) 316-1983 or (785) 838-9310 and using conference ID NUWEQ2. An audio archive of the webcast will be available following the call on the Investors page.

About Aquadex

The Aquadex SmartFlow System is indicated for the continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for... (truncated)signed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.

Financial statements

Income Statement

Three months ended June 30 — (in thousands, except per share amounts and weighted average shares outstanding)

Three months ended June 30 – 2026Three months ended June 30 – 2025Six months ended June 30 – 2026Six months ended June 30 – 2025
Net sales1,9691,7254,3723,629
Cost of goods sold4717671,1901,604
Gross profit1,4989583,1822,025
Operating expenses:Selling, general and administrative3,7253,1898,2496,766
Operating expenses:Research and development9426752,6701,225
Operating expenses:Total operating expenses4,6673,86410,9197,991
Operating expenses:Loss from operations-3,169-2,906-7,737-5,966
Operating expenses:Other income710817
Operating expenses:Financing expense-6,077-10,553-6,077-10,553
Operating expenses:Change in fair value of warrant liabilities4,4119004,437940
Operating expenses:Loss before income taxes-4,828-12,549-9,369-15,562
Operating expenses:Income tax expense-4-5
Operating expenses:Net loss-4,828-12,553-9,369-15,567
Operating expenses:Deemed dividend attributable to Series J Convertible Preferred Stock1132
Operating expenses:Net loss attributable to common shareholders-4,827-12,552-9,366-15,565
Operating expenses:Basic and diluted loss per share-26.64-2,134.19-77.9-3,514.87
Operating expenses:Weighted average shares outstanding – basic and diluted181,2435,881120,2634,428
Other comprehensive loss:Net Loss-4,828-12,553-9,369-15,567
Other comprehensive loss:Foreign currency translation adjustments-5-7
Other comprehensive loss:Total comprehensive loss-4,828-12,558-9,369-15,574

Balance Sheet

June 30, 2026 — (in thousands, except share and per share amounts)

June 30, 2026 – (Unaudited)December 31, 2025
Current assetsCash and cash equivalents3,9221,085
Current assetsAccounts receivable1,5451,493
Current assetsInventories, net1,7421,910
Current assetsOther current assets690698
Current assetsTotal current assets7,8995,186
Current assetsProperty, plant and equipment, net347368
Current assetsOperating lease right-of-use asset179293
Current assetsIntangible assets, net102
Current assetsOther assets599271
Current assetsTOTAL ASSETS9,1266,118
Current liabilitiesAccounts payable and accrued liabilities2,8962,226
Current liabilitiesAccrued compensation731460
Current liabilitiesCurrent portion of operating lease liability200261
Current liabilitiesDeferred consideration from Rendiatech acquisition, current113
Current liabilitiesOther current liabilities6885
Current liabilitiesTotal current liabilities4,0083,032
Current liabilitiesDeferred consideration from Rendiatech acquisition, non-current200
Current liabilitiesWarrant liabilities6,963389
Current liabilitiesOperating lease liability67
Current liabilitiesTotal liabilities11,1713,488
Commitments and contingenciesMezzanine Equity Series J Convertible Preferred Stock as of June 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 600,000 shares, issued and outstanding 159 and 137, respectively106
Stockholders’ equity (deficit)Additional paid‑in capital323,618318,928
Accumulated other comprehensive income:Foreign currency translation adjustment88
Accumulated other comprehensive income:Accumulated deficit-325,681-316,312
Accumulated other comprehensive income:Total stockholders’ equity (deficit)-2,0552,624
Accumulated other comprehensive income:TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)9,1266,118

Cash Flow

Six Months ended June 30 — (in thousands)

Six Months ended June 30 – 2026Six Months ended June 30 – 2025
Operating Activities:Net loss-9,369-15,567
Adjustments to reconcile net loss to cash flows used in operating activities:Depreciation and amortization75123
Adjustments to reconcile net loss to cash flows used in operating activities:Stock-based compensation expense4784
Adjustments to reconcile net loss to cash flows used in operating activities:Change in fair value of warrant liabilities-4,437-940
Adjustments to reconcile net loss to cash flows used in operating activities:Financing expense6,07710,553
Adjustments to reconcile net loss to cash flows used in operating activities:Non-cash IP R&D from Rendiatech acquisition757
Changes in operating assets and liabilities:Accounts receivable-52534
Changes in operating assets and liabilities:Inventory, net218-310
Changes in operating assets and liabilities:Other current assets8-430
Changes in operating assets and liabilities:Other assets-213106
Changes in operating assets and liabilities:Other liabilities-144-74
Changes in operating assets and liabilities:Accounts payable and accrued expenses7461,288
Changes in operating assets and liabilities:Net cash used in operating activities-6,287-4,633
Investing Activities:Purchases of property and equipment-39-4
Investing Activities:Purchase of intangible assets-90
Investing Activities:Cash paid for acquisition of Rendiatech, net of cash acquired-164
Investing Activities:Net cash used in investing activities-293-4
Financing Activities:Proceeds from issuance of common stock and warrants, net9,3633,999
Financing Activities:Issuance of common stock from ATM, net55
Financing Activities:Net cash provided by financing activities9,4183,999
Financing Activities:Effect of exchange rate changes on cash-7
Full release

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC.

Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:

CORE IR ir@nuwellis.com

Media Contact:

CORE PR media@nuwellis.com

NUWELLIS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

NUWELLIS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except per share amounts and weighted average shares outstanding)

NUWELLIS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

Supplemental cash flow information

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.